Association of antioxidant deficiency and the level of products of protein and lipid peroxidation in patients with the first episode of schizophrenia

Пятойкина, А. С.; Lyakhova, Anastasia Alexandrovna; Semennov, Ilya Vladimirovich; Мазо, Г. Э.; Kostina, O. V.; Жукова, Е. С.; Shcherbatyuk, T G; Kasyanov, E. D.; Благонравова, А С

doi:10.1007/s12031-021-01884-w

Cited by 7 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most antipsychotics inhibit serotonin reuptake, which can alter functioning of the hypothalamic-pituitary-gonadal (HPG) axis and thus may alter prolactin secretion and thereby cause menstrual disturbances ( Huhn et al, 2019 ; Solmi et al, 2020 ), including heavy menstrual bleeding (HMB), hypomenorrhea, or amenorrhea ( Haddad and Wieck, 2004 ; Kumar et al, 2013 ; Besag et al, 2021 ). Furthermore, HPG axis dysfunction can also cause glucose and lipid metabolism disorders that can lead to excessive weight gain and obesity ( An et al, 2018 ; Tian et al, 2021 ; Piatoikina et al, 2022 ). Obesity is associated with dysregulation of adipose tissue functions and aberrations in adipokine secretion that can alter inflammatory responses, endothelial cell functions, and coagulation pathways.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Heavy Menstrual Bleeding and Its Associated Cognitive Risks and Predictive Factors in Women With Severe Mental Disorders

et al. 2022

View full text Add to dashboard Cite

There has been limited studies examining treatment-induced heavy menstrual bleeding (HMB) in women with severe mental illnesses. The aim of this study was to examine HMB prevalence and HMB-associated factors in young women (18–34 years old) diagnosed with bipolar disorder (BP), major depressive disorder (MDD), or schizophrenia (SCZ) who have full insight and normal intelligence. Eighteen-month menstruation histories were recorded with pictorial blood loss assessment chart assessments of HMB. Multivariate analyses were conducted to obtain odds ratios (ORs) and 95% confidence intervals (CIs). Drug effects on cognition were assessed with the MATRICS Consensus Cognitive Battery (MCCB). HMB prevalence were: BP, 25.85%; MDD, 18.78%; and SCH, 13.7%. High glycosylated hemoglobin (HbA1c) level was a strong risk factor for HMB [BP OR, 19.39 (16.60–23.01); MDD OR, 2.69 (4.59–13.78); and SCZ OR, 9.59 (6.14–12.43)]. Additional risk factors included fasting blood sugar, 2-h postprandial blood glucose, and use of the medication valproate [BP: OR, 16.00 (95%CI 12.74–20.22); MDD: OR, 13.88 (95%CI 11.24–17.03); and SCZ OR, 11.35 (95%CI 8.84–19.20)]. Antipsychotic, antidepressant, and electroconvulsive therapy use were minor risk factors. Pharmacotherapy-induced visual learning impairment was associated with HMB [BP: OR, 9.01 (95%CI 3.15–13.44); MDD: OR, 5.99 (95%CI 3.11–9.00); and SCZ: OR, 7.09 (95%CI 2.99–9.20)]. Lithium emerged as a protective factor against HMB [BP: OR, 0.22 (95%CI 0.14–0.40); MDD: OR, 0.30 (95%CI 0.20–0.62); and SCZ: OR, 0.65 (95%CI 0.33–0.90)]. In SCZ patients, hyperlipidemia and high total cholesterol were HMB-associated factors (ORs, 1.87–2.22). Psychiatrist awareness of HMB risk is concerningly low (12/257, 2.28%). In conclusion, prescription of VPA should be cautioned for women with mental illness, especially BP, and lithium may be protective against HMB.

show abstract